Alendronate and pharmacological doses of 1α OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia

Journal of Bone and Mineral Metabolism

Volumn 20, Issue 3, 2002, Pages 170-173

  Yamamoto, Takehisa ^a,c   Ozono, Keiichi ^b   Shima, Masaaki ^a   Yoshikawa, Hideki ^a   Okada, Shintaro ^a  

^a OSAKA UNIVERSITY   (Japan)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c Minoh City Hospital   (Japan)

Author keywords

1,25(OH)2D; Alendronate; Fibroblast growth factor 23; Humoral factor; Hypophosphatemia

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCIUM LACTATE; PHOSPHATE; 1-HYDROXYCHOLECALCIFEROL; CALCIUM DERIVATIVE; HYDROXYCOLECALCIFEROL; LACTIC ACID DERIVATIVE;

ADULT; ALBRIGHT SYNDROME; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHOSPHATEMIA; PRIORITY JOURNAL; SCINTIGRAPHY; TREATMENT OUTCOME; BONE; DRUG COMBINATION; METABOLISM; SCINTISCANNING;

ADULT; ALENDRONATE; BONE AND BONES; CALCIUM COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; FIBROUS DYSPLASIA, POLYOSTOTIC; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPOPHOSPHATEMIA; LACTATES; PHOSPHATES;

EID: 0347086214     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007740200024     Document Type: Article

References (19)

1. Whyte MP (1999) Fibrous dysplasia. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th edn. Lippincott-Raven, Philadelphia, pp 384-386
2. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
3. Schwindinger WF, Francomano CA, Levine MA (1992) Identification of a mutation in the gene encoding the α subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 89:5152-5156
4. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L (1989) GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature 34:692-696
5. Yamamoto T, Ozono K, Kasayama S, Yamaoka K, Kishimoto T, Okada S (1996) Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 98:30-35
6. Zung A, Chaleur SA, Schwindinger WF, Levine MA, Phillip M, Jara A, Counts DR, Kowaski AA (1995) Urinary cyclic adenosine 3′-5′mono-phosphate response in McCune-Albright syndrome: clinical evidence for altered renal adenylyl cyclase activity. J Clin Endocrinol Metab 80:3576-3581
7. Caverzasio J, Rizzoli R, Bonjour JP (1986) Sodium-dependent phosphate transport inhibited by parathyroid hormone and cyclic AMP stimulation in an opossum kidney cell line. J Biol Chem 261:3233-3237
8. Dent VE, Gertner JM (1976) Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med 179:411-420
9. Yamamoto T, Miyamoto K, Ozono K, Taketani Y, Katai K, Miyauchi A, Shima M, Yoshikawa H, Yoh K, Takeda E, Okada S (2001) Hypophosphatemic rickets accompanying McCune-Albright syndrome: evidence that a humoral factor causes hypophosphatemia. J Bone Miner Metab 19:287-295
10. Chapurlat R, Delmas PD, Liens D, Meunier PJ (1997) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746-1752
11. Walton RJ, Bijvoet OLM (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet II:309-310
12. Watts NB (1999) Pharmacology of agents to treat osteoporosis. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th edn. Lippincott-Raven, Philadelphia, pp 278-283
13. Drezner MK (1999) Tumor-induced osteomalacia. In: Favus MJ (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th edn. Lippincott-Raven, Philadelphia, pp 331-337
14. Miyauchi A, Fukase M, Tsutsumi M, Fujita T (1988) Hemangiocytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. J Clin Endocrinol Metab 67:46-53
15. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Characterization of FGF23 as a causative factor of tumor induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
16. The ADHR Consortium (2000) Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nature Genet 26:345-348
17. Sahni M, Guenther HL, Fleish H, Collin P, Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011
18. 2D in response to inhibition of bone resorption. Am J Physiol 254:E260-264
19. Nagao Y, Ishitobi Y, Kinoshita H, Fukushima S, Kawashima H (1991) YM175, a new bisphosphonate, increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity. Biochem Biophys Res Commun 180:1172-1178